CUE
Cue Biopharma·NASDAQ
--
--(--)
--
--(--)
3.80 / 10
Netural
Sentiment is neutral (3.8) but fund flow is good (7.6), with small/medium inflows positive and large blocks negative. Analysts are overwhelmingly bullish (100% Strong Buy) yet only one analyst with a poor track record, and market outlook remains pessimistic.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-25
InstitutionLUCID CAPITAL MARKETS
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for CUE?
- CUE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.80/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
